“…The beta rebound has been proposed to reflect the functional state of the SMI cortex in various neurological diseases such as stroke (Laaksonen et al, 2012;Parkkonen et al, 2017;Tang et al, 2020), schizophrenia (Brookes et al, 2015;Liddle et al, 2016), Parkinson's disease (Degardin et al, 2009;Hall et al, 2014;Vinding et al, 2019), and cerebral palsy (Demas et al, 2019;Pihko et al, 2014). However, patients are prone to changes in their alertness during MEG/EEG recordings, which may alter the oscillatory activity, and thus potentially affect the estimated cortical level of excitability.…”